Actively Recruiting
Phase III Study Comparing GB06 and Norditropin FlexPro for Treating Growth Hormone Deficiency in Children Aged 3 to 11
Led by Kexing Biopharm Co., Ltd. · Updated on 2026-06-10
192
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
This trial investigates the use of GB06, a biosimilar to Norditropin4 FlexPro4, to treat children with growth hormone deficiency GHD, which causes short stature and other health issues like altered body composition and increased cardiovascular risks. The study aims to compare the yearly height growth rate of children treated with GB06 versus those receiving Norditropin4 FlexPro4 over one year to assess if GB06 works similarly and is safe for pediatric patients. Participants in this study will receive either GB06 or Norditropin4 FlexPro4 by daily subcutaneous injections at a dosage of 0.035 mgkg for 52 consecutive weeks. This is a randomized, open-label trial where children aged 3 to 11 years will be assigned to one of these two treatment groups to evaluate and compare the effects on growth over the treatment period. During the study, participants will undergo regular assessments including measurements of annual height velocity at several timepoints up to 52 weeks, bone age evaluations, Tanner staging, and blood tests for IGF-1, IGFBP-3 levels, and antibody presence. Safety will be monitored throughout the treatment and for 56 weeks after, with detailed tracking of any adverse events. The total involvement lasts for over a year with multiple visits to assess growth and health changes.
CONDITIONS
Brief Title
GB06 Phase III Trial for Pediatric Growth Hormone Deficiency
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here